The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells

Gross, 1989, Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proc. Natl. Acad. Sci. U. S. A., 86, 10024, 10.1073/pnas.86.24.10024

June, 2018, CAR T cell immunotherapy for human cancer, Science, 359, 1361, 10.1126/science.aar6711

Sadelain, 2016, Chimeric antigen receptors: driving immunology towards synthetic biology, Curr. Opin. Immunol., 41, 68, 10.1016/j.coi.2016.06.004

Cartellieri, 2010, Chimeric antigen receptor-engineered T cells for immunotherapy of cancer, J. Biomed. Biotechnol., 2010, 10.1155/2010/956304

Guedan, 2018, Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation, JCI Insight, 3, pii: 96976, 10.1172/jci.insight.96976

Töpfer, 2015, DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy, J. Immunol., 194, 3201, 10.4049/jimmunol.1400330

Chmielewski, 2017, CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors, Cell Rep., 21, 3205, 10.1016/j.celrep.2017.11.063

Kloss, 2013, Sadelain M.COmbinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat. Biotechnol., 31, 71, 10.1038/nbt.2459

Albert, 2019, Tonic signaling and its effects on lymphopoiesis of CAR-Armed hematopoietic stem and progenitor cells, J. Immunol., 202, 1735, 10.4049/jimmunol.1801004

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci. Transl. Med., 3

Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci. Transl. Med., 5

Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci. Transl. Med., 7

Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci. Transl. Med., 6

Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J. Clin. Oncol., 33, 540, 10.1200/JCO.2014.56.2025

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222

Garfall, 2015, Chimeric antigen receptor t cells against CD19 for multiple myeloma, N. Engl. J. Med., 373, 1040, 10.1056/NEJMoa1504542

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

June, 2018, CAR T cell immunotherapy for human cancer, Science, 359, 1361, 10.1126/science.aar6711

Brudno, 2018, Chimeric antigen receptor T-cell therapies for lymphoma, Nat. Rev. Clin. Oncol., 15, 31, 10.1038/nrclinonc.2017.128

Maude, 2018, Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia, N. Engl. J. Med., 378, 439, 10.1056/NEJMoa1709866

Neelapu, 2017, Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma, N. Engl. J. Med., 377, 2531, 10.1056/NEJMoa1707447

Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751

Hoyos, 2010, Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety, Leukemia, 24, 1160, 10.1038/leu.2010.75

Fedorov, 2013, PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses, Sci. Transl. Med., 5

Mollanoori, 2018, CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment, Hum. Immunol., 79, 876, 10.1016/j.humimm.2018.09.007

Di Stasi, 2011, Inducible apoptosis as a safety switch for adoptive cell therapy, N. Engl. J. Med., 365, 1673, 10.1056/NEJMoa1106152

Paszkiewicz, 2016, Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia, J. Clin. Invest., 126, 4262, 10.1172/JCI84813

Fasslrinner, 2019, Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukemia, B. J. Hematol., 10.1111/bjh.15975

Urbanska, 2012, A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor, Cancer Res., 72, 1844, 10.1158/0008-5472.CAN-11-3890

Dale, 1994, Antibodies against biotinylated proteins are present in normal human serum, J. Lab. Clin. Med., 123, 365

Goebeler, 2016, Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy, Leuk. Lymphoma, 57, 1021, 10.3109/10428194.2016.1161185

Stamova, 2012, Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses, Anal. Biochem., 423, 261, 10.1016/j.ab.2011.12.042

Stamova, 2012, Cancer immunotherapy by retargeting of immune effector cells via recombinant bispecific antibody constructs, Antibodies, 1, 172, 10.3390/antib1020172

Arndt, 2013, Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells, Leukemia, 27, 964, 10.1038/leu.2013.18

Feldmann, 2012, Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells, J. Immunol., 189, 3249, 10.4049/jimmunol.1200341

Koristka, 2013, Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B, J. Autoimmun., 42, 105, 10.1016/j.jaut.2013.01.002

Arndt, 2014, Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells, Prostate, 74, 1347, 10.1002/pros.22851

Arndt, 2014, Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system, Prostate, 74, 1335, 10.1002/pros.22850

Arndt, 2014, Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system, Leukemia, 28, 59, 10.1038/leu.2013.243

Koristka, 2014, Flexible antigen-specific redirection of human regulatory t cells via a novel universal chimeric antigen receptor system, Blood, 124, 3494, 10.1182/blood.V124.21.3494.3494

Cao, 2016, Design of switchable chimeric antigen receptor t cells targeting breast Cancer, Angew. Chem. Int. Ed. Engl., 55, 7520, 10.1002/anie.201601902

Ma, 2016, Versatile strategy for controlling the specificity and activity of engineered T cells, Proc. Natl. Acad. Sci. U. S. A., 113, E450, 10.1073/pnas.1524193113

Rodgers, 2016, Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies, Proc. Natl. Acad. Sci. U. S. A., 113, E459, 10.1073/pnas.1524155113

Feldmann, 2017, Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR", Oncotarget, 8, 31368, 10.18632/oncotarget.15572

Albert, 2017, A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform, Oncoimmunology, 6

Mitwasi, 2017, Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells, Oncotarget, 8, 108584, 10.18632/oncotarget.21017

Albert, 2018, From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo, Oncotarget, 9, 25597, 10.18632/oncotarget.25390

Loureiro, 2018, Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells, Blood Cancer J., 8, 81, 10.1038/s41408-018-0113-4

Bachmann, 2017, Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells, Oncotarget, 9, 7487

Cartellieri, 2016, Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts, Blood Cancer J., 6

Carmo-Fonseca, 1989, Identification of La ribonucleoproteins as a component of interchromatin granules, Exp. Cell Res., 185, 73, 10.1016/0014-4827(89)90038-4

Tröster, 1994, One gene, two transcripts: isolation of an alternative transcript encoding for the autoantigen La/SS-B from a cDNA library of a patient with primary Sjögrens’ syndrome, J. Exp. Med., 180, 2059, 10.1084/jem.180.6.2059

Yiannaki, 1998, The value of synthetic linear epitope analogues of La/SSB for the detection of autoantibodies to La/SSB; specificity, sensitivity and comparison of methods, Clin. Exp. Immunol., 112, 152, 10.1046/j.1365-2249.1998.00558.x

Tröster, 1995, Activation of a murine autoreactive B cell by immunization with human recombinant autoantigen La/SS-B: characterization of the autoepitope, J. Autoimmun., 8, 825, 10.1016/S0896-8411(95)80020-4

Dudek, 2007, T cell epitopes of the La/SSB autoantigen in humanized transgenic mice expressing the HLA class II haplotype DRB1*0301/DQB1*0201, Arthritis Rheum., 56, 3387, 10.1002/art.22870

Malik, 2007, Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients, Lupus, 16, 863, 10.1177/0961203307083365

Semsei, 1993, Cloning of the autoantigen La/SS-B from a rat cDNA library: detection of species specific variations, Gene, 126, 265, 10.1016/0378-1119(93)90378-G

Aliperta, 2017, Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy, Sci. Rep., 7, 42855, 10.1038/srep42855

Aliperta, 2015, Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts, Blood Cancer J., 5, e348, 10.1038/bcj.2015.73

Le Gall, 1999, Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding, FEBS Lett., 453, 164, 10.1016/S0014-5793(99)00713-9